Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-HLA-A2/NY-ESO1 TCR-transduced Autologous T cells, Autologous Anti-HLA-A2/NY-ESO1 TCR-transduced T Lymphocytes, Autologous HLA-A2/NY-ESO-1-specific TCR Gene-transduced T-lymphocytes

Pipeline

Phase 1: 1

Top Sponsors

University of Southern California1

Indications

Triple Negative Breast Cancer1
Breast Cancer1
Cancer1

Los Angeles, California1 trial

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

USC / Norris Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.